Robert Ross Buys Shares of XLO $XLO
Key Points
- Robert Ross bought 5,000 shares of Xilio Therapeutics, Inc. ($XLO).
- $XLO last traded around $8.31.
Robert Ross, insider at Xilio Therapeutics, Inc. ($XLO), bought 5,000 shares at an average price of $0.00. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Xilio Therapeutics, Inc. ($XLO) Stock
Xilio Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.